# From Innate to Adaptive: Paradigm Shifts and Frontier Challenges in Next-Generation Vaccine Design

**Authors:** Siqi Huang, Shaochen Yu, Mengjie Zhang, Yuting Huang, Beibei Tian, Jian Lu

PMC · DOI: 10.3390/vaccines14030228 · Vaccines · 2026-02-28

## TL;DR

This paper reviews how modern vaccines are shifting from traditional methods to using advanced immune system insights and technologies for better protection.

## Contribution

The paper introduces a conceptual framework for next-generation vaccines based on integrating computational design, adjuvant control, and intelligent delivery.

## Key findings

- The innate immune system plays a key role in shaping adaptive immune responses to vaccines.
- Germinal centers act as micro-evolutionary engines for antibody maturation influenced by vaccine design.
- Combining systems vaccinology, AI, and personalized medicine is advancing vaccine predictability and response speed.

## Abstract

The unprecedented success of mRNA vaccines during the COVID-19 pandemic marks a fundamental paradigm shift in vaccinology, moving the field from empirical pathogen modification toward the rational engineering of host immunity. This review synthesizes recent breakthroughs to construct a conceptual framework for understanding how modern vaccines function as programmable immune instructions. We first analyze the innate immune system as an instructional center, where recognition of vaccine components dictates the quality of ensuing adaptive responses. We then examine the germinal center (GC) as a micro-evolutionary engine for antibody maturation, the output of which can be tuned by vaccine design. The discussion centers on three integrated pillars of next-generation vaccines: computationally designed immunogens, spatiotemporally controlled adjuvant systems, and intelligent delivery platforms, emphasizing that their synergy is essential for achieving broad, durable protection against complex pathogens. Finally, we explore how the convergence of systems vaccinology, artificial intelligence, and personalized medicine is guiding the field toward a more predictable and rapid-response future, while also outlining key advances and persistent challenges.

## Linked entities

- **Diseases:** COVID-19 (MONDO:0100096)

## Full-text entities

- **Genes:** BCR (BCR activator of RhoGEF and GTPase) [NCBI Gene 613] {aka ALL, BCR1, CML, D22S11, D22S662, PHL}, CGAS (cyclic GMP-AMP synthase) [NCBI Gene 115004] {aka C6orf150, D4, MB21D1, h-cGAS}, RIGI (RNA sensor RIG-I) [NCBI Gene 23586] {aka DDX58, RIG-I, RIG1, RLR-1, SGMRT2}, CD40LG (CD40 ligand) [NCBI Gene 959] {aka CD154, CD40L, HIGM1, IGM, IMD3, T-BAM}, TLR9 (toll like receptor 9) [NCBI Gene 54106] {aka CD289}, ERVK-6 (endogenous retrovirus group K member 6, envelope) [NCBI Gene 64006] {aka ERVK6, HERV-K(C7), HERV-K108, K-Rev, c-orf, cORF}, CD86 (CD86 molecule) [NCBI Gene 942] {aka B7-2, B7.2, B70, BU63, CD28LG2, CD86 v6}, CD40 (CD40 molecule) [NCBI Gene 958] {aka Bp50, CDW40, TNFRSF5, p50}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, IFNA8 (interferon alpha 8) [NCBI Gene 3445] {aka IFN-alphaB}, CD80 (CD80 molecule) [NCBI Gene 941] {aka B7, B7-1, B7.1, BB1, CD28LG, CD28LG1}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, IL21 (interleukin 21) [NCBI Gene 59067] {aka CVID11, IL-21, Za11}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, IL15 (interleukin 15) [NCBI Gene 3600] {aka IL-15}, NECTIN1 (nectin cell adhesion molecule 1) [NCBI Gene 5818] {aka CD111, CLPED1, ED4, HIgR, HV1S, HVEC}, LOC102723996 (ICOS ligand) [NCBI Gene 102723996], CD69 (CD69 molecule) [NCBI Gene 969] {aka AIM, BL-AC/P26, CLEC2C, EA1, GP32/28, MLR-3}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, ITGAE (integrin subunit alpha E) [NCBI Gene 3682] {aka CD103, HUMINAE}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061] {aka ERIS, MITA, MPYS, NET23, SAVI, STING}
- **Diseases:** influenza (MESH:D007251), infectious disease (MESH:D003141), fever (MESH:D005334), cowpox (MESH:D015605), hypersensitivity (MESH:D004342), inflammation (MESH:D007249), TB (MESH:D014390), COVID-19 (MESH:D000086382), hemolytic (MESH:D006461), cancer (MESH:D009369), measles (MESH:D008457), X (MESH:D000326), toxicity (MESH:D064420), Bell's palsy (MESH:D020330), HIV (MESH:D015658), injury to (MESH:D014947), rabies (MESH:D011818), infection (MESH:D007239), death (MESH:D003643), tuberculosis (MESH:D014376), malaria (MESH:D008288)
- **Chemicals:** proline (MESH:D011392), glycol (MESH:D006018), MVA (MESH:C051113), CpG (MESH:C015772), ester (MESH:D004952), saponin (MESH:D012503), PEG (MESH:D011092), phospholipids (MESH:D010743), glutathione (MESH:D005978), polyester (MESH:D011091), lipid (MESH:D008055), polysaccharide (MESH:D011134), cholesterol (MESH:D002784), AS04 (-), MPL (MESH:C048436), polymer (MESH:D011108), Resiquimod (MESH:C402365), disulfide (MESH:D004220), QS-21 (MESH:C078785)
- **Species:** Escherichia coli (E. coli, species) [taxon 562], Hepatovirus A (no rank) [taxon 12092], Respiratory syncytial virus (no rank) [taxon 12814], Gammacoronavirus (genus) [taxon 694013], Enterovirus C (no rank) [taxon 138950], Adenoviridae (family) [taxon 10508], Leishmania (subgenus) [taxon 38568], Homo sapiens (human, species) [taxon 9606], Mycobacterium tuberculosis (species) [taxon 1773], Human immunodeficiency virus (species) [taxon 12721], Variola virus (smallpox virus, no rank) [taxon 10255], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Vesicular stomatitis virus (species) [taxon 11276], Human immunodeficiency virus 1 (no rank) [taxon 11676], Betacoronavirus (genus) [taxon 694002]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13030370/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13030370/full.md

## References

61 references — full list in the complete paper: https://tomesphere.com/paper/PMC13030370/full.md

---
Source: https://tomesphere.com/paper/PMC13030370